The JI PBL Intereron Source
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     
 

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Berahovich, R. D.
Right arrow Articles by Schall, T. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Berahovich, R. D.
Right arrow Articles by Schall, T. J.
The Journal of Immunology, 2005, 174: 7341-7351.
Copyright © 2005 by The American Association of Immunologists

Proteolytic Activation of Alternative CCR1 Ligands in Inflammation1

Robert D. Berahovich2,3, Zhenhua Miao2, Yu Wang, Brett Premack, Maureen C. Howard and Thomas J. Schall

ChemoCentryx, Mountain View, CA 94043


   Abstract
Top
 Abstract
Introduction
 Materials and Methods
 Results
 Discussion
 Disclosures
 References
 
Although chemokines CCL3/MIP-1{alpha} and CCL5/RANTES are considered to be primary CCR1 ligands in inflammatory responses, alternative CCR1 ligands have also been described. Indeed, four such chemokines, CCL6/C10/MIP-related protein-1, CCL9/MIP-1{gamma}/MIP-related protein-2, CCL15/MIP-1{delta}/hemofiltrate CC chemokine-2/leukotactin-1, and CCL23/CK{beta}8/myeloid progenitor inhibitory factor-1, are unique in possessing a separately encoded N-terminal domain of 16–20 residues and two additional precisely positioned cysteines that form a third disulfide bridge. In vitro, these four chemokines are weak CCR1 agonists, but potency can be increased up to 1000-fold by engineered or expression-associated N-terminal truncations. We examined the ability of proinflammatory proteases, human cell supernatants, or physiological fluids to perform N-terminal truncations of these chemokines and thereby activate their functions. Remarkably, most of the proteases and fluids removed the N-terminal domains from all four chemokines, but were relatively unable to cleave the truncated forms further. The truncated chemokines exhibited up to 1000-fold increases in CCR1-mediated signaling and chemotaxis assays in vitro. In addition, N-terminally truncated CCL15/MIP-1{delta} and CCL23/CK{beta}8, but not CCL3/MIP-1{alpha} or CCL5/RANTES, were detected at relatively high levels in synovial fluids from rheumatoid arthritis patients. These data suggest that alternative CCR1 ligands are converted into potent chemoattractants by proteases released during inflammatory responses in vivo.


   Introduction
Top
 Abstract
 Introduction
Materials and Methods
 Results
 Discussion
 Disclosures
 References
 
Among the family of {beta} chemokines, only four members, CCL6, CCL9, CCL15, and CCL23, possess an extended N-terminal domain upstream of the chemokine body. This domain contains 16–20 aa, including multiple basic and acidic residues, and is encoded by a separate exon (1, 2, 3). The N-terminal domains of the two human chemokines CCL15 (MIP-1{delta}/hemofiltrate CC chemokine (HCC)4-2/MIP-5/leukotactin-1) and CCL23 (CK{beta}8/myeloid progenitor inhibitory factor (MPIF)-1/MIP-3) are nearly identical, whereas those of the two mouse chemokines, CCL6 (C10/MIP-related protein (MRP)-1) and CCL9 (MIP-1{gamma}/MRP-2), are very different from each other and the two human chemokines. Human forms of CCL6 and CCL9 and murine forms of CCL15 and CCL23 have not been described. All four chemokines are relatively weak ligands for CCR1 and contain precisely positioned fifth and sixth cysteine residues that appear to form a third disulfide bond (2, 4). In this report we refer to these four chemokines as the NC6 chemokine subfamily.

Although the functions of the NC6 chemokines in vivo are unknown, several lines of evidence suggest that their N-terminal domains may serve as regulators of chemokine activity. For example, the N-terminal domains seem to be removed by endogenous proteases during chemokine expression or purification. Purification of CCL23/CK{beta}8 from a baculovirus system in the absence of protease inhibitors yielded not only the full 99-residue chemokine, but also shorter forms with deletions of the N-terminal domain (5). rCCL15/MIP-1{delta} produced via baculovirus was detected as two forms: 12 and 9 kDa (6). Natural (nonrecombinant) CCL9/MIP-1{gamma} was also detected as two forms, 10.5 and 9 kDa, in conditioned medium from the murine dendritic cell line XS52 (7). The expression of CCL15/MIP-1{delta} in yeast (2) and mammalian cells (8) resulted in only one form each, but the apparent sizes (7 and 8 kDa, respectively) suggested that truncations had occurred.

Second, NC6 chemokines lacking the N-terminal domains have substantially increased potency. rCCL6/C10 with an engineered deletion of the N-terminal domain was at least 10-fold more potent than recombinant wild-type C10 in chemotaxis assays using murine peritoneal exudate cells or human PBMC (9). rCCL23/CK{beta}8 with a deletion of the N-terminal domain was found to exhibit >100-fold increased potency in CCR1-mediated calcium mobilization and chemotaxis in human monocytes (5), correlating with increased affinity for CCR1 (10). rCCL15/MIP-1{delta} lacking the N-terminal domain was similarly reported to exhibit 100-fold greater potency on CCR1 transfectants (11). However, not all investigators observed increased potency after removal of the N-terminal domain (12).

We examined the conditions in vivo in which NC6 chemokines might become activated by proteolytic removal of their N-terminal domains. Although little is known about NC6 chemokine biology in vivo, the use of CCR1 by these chemokines suggests that they might function in local inflammatory responses to foreign entities. Initial detection of foreign entities by resident tissue macrophages, dendritic cells, or mast cells results in, among other events, rapid secretion of the proinflammatory chemokines CCL3/MIP-1{alpha}, CCL5/RANTES, CCL11/eotaxin, and the MCPs (CCL2, -7, -8, and -13). These chemokines enter nearby blood vessels and, via chemokine receptors CCR1, -2, -3, and -5, recruit/activate effector leukocytes including neutrophils, eosinophils, and monocyte/macrophages. Mast cells and infiltrating neutrophils release high levels of proteases that degrade extracellular matrix components and initiate antimicrobial events (13). Thus, if an NC6 chemokine is present at the site of inflammation, these proteases might be envisioned to remove the chemokine’s regulatory N-terminal domain.

In this study we examined whether inflammatory fluids or purified proteases released from activated mast cells and neutrophils remove the N-terminal domains from the NC6 chemokines and, in so doing, enhance their function. Each of the four NC6 chemokines was exposed in vitro to recombinant mast cell chymase, purified neutrophil cathepsin G or elastase, activated neutrophil-conditioned medium, or synovial fluids from highly inflamed knee joints. The results show clearly that such conditions result in partial or complete removal of the inhibitory N-terminal domain and activation of CCR1-mediated calcium mobilization and cell migration in vitro. In addition, synovial fluids from rheumatoid arthritis patients and subjects with knee injuries were found to contain N-terminally truncated CCL15/MIP-1{delta} and CCL23/CK{beta}8 at concentrations more than sufficient to activate a biological response. In contrast, the traditional CCR1 ligands, CCL3/MIP-1{alpha} and CCL5/RANTES, were wholly or partially inactivated by the proteases and fluids in vitro. Moreover, CCL3/MIP-1{alpha} and CCL5/RANTES were detected in synovial fluids from only a subset of rheumatoid arthritis patients, at concentrations insufficient to activate a biological response. Thus, we postulate that naturally occurring proteolytic processes at inflammatory sites can amplify an immune response by the ready conversion of NC6 chemokines to their activated state (designated NC6*) in situ.


   Materials and Methods
Top
 Abstract
 Introduction
 Materials and Methods
Results
 Discussion
 Disclosures
 References
 
Chemokines, proteases, and cells

Recombinant CCL6/C10, CCL9/MIP-1{gamma}, CCL15/MIP-1{delta} (92 aa), CCL15{Delta}24/leukotactin (LKN)-1 (68 aa), CCL23/CK{beta}8 (22–120 aa), and CCL23{Delta}24/MPIF-1 (46–120 aa) were purchased from R&D Systems. Purified enzymes Asp-N, elastase, and cathepsin G were purchased from Sigma-Aldrich. Recombinant human chymase was a gift from N. Schechter (University of Pennsylvania, Philadelphia, PA). Human synovial fluids from inflamed knee joints were either donated or purchased from Bioreclamation. Human neutrophils were purified from healthy donors by sedimentation in DEAE-dextran and lysis of contaminating erythrocytes in PharmLyse (BD Biosciences). The neutrophils were cultured in serum-free RPMI 1640 medium (HyClone) containing 0.1 µg/ml PMA and 1 µg/ml ionomycin (both from Sigma-Aldrich) for 6 h at 37°C in a humidified incubator containing 5% CO2. The conditioned medium (PMN sup) was collected as the supernatant after low speed centrifugation of the cultures to remove the cells. PMA and ionomycin-treated neutrophil supernatants were used in these studies, because supernatants from neutrophils treated with LPS, a physiologically relevant activator, were less active for proteolysis.

Human monocytes were obtained from buffy coats purchased from the Stanford Blood Bank by sedimentation on Ficoll-Paque (Amersham Biosciences) and selection with anti-CD14 magnetic beads (Miltenyi Biotec) according to the manufacturers’ instructions. For generation of dendritic cells, monocytes were cultured for 6 days in RPMI 1640 medium containing 10% FBS (HyClone). On days 0, 2, and 4, GM-CSF and IL-4 (both purchased from R&D Systems) were added to the cultures at 1000 WHO U/ml each. The cells were confirmed to be CD14–CD1a+ immature DC by FACS staining on day 6.

Chemokine digest and SDS-PAGE

Typically, 10 µg of each NC6 chemokine was mixed with 0.1–0.4 µg of each enzyme, 4 µl of synovial fluid, or 20 µl PMN sup in a 40-µl volume reaction containing 100 mM Tris-HCl (pH 7.8) and 10 mM CaCl2. The mixtures were incubated at 37°C up to 24 h, then frozen for later analysis. For visualization of chemokine cleavage fragments, 8 µl of each digest was mixed with 2 µl of 1 M DTT (Sigma-Aldrich) and 10 µl Tricine sample buffer (Invitrogen Life Technologies), heated to 90°C for 3 min, and subjected to denaturing gel electrophoresis on 10–20% acrylamide Tricine minigels (Invitrogen Life Technologies) at 125 V for 1 h. The gels were then rinsed three times for 10 min each time with water, immersed in GelCode Blue reagent (Pierce) for 1 h with gentle shaking, and destained in water for 2–18 h. For N-terminal sequencing, cleavage products were electroblotted onto Immobilon-PSQ membranes (Sigma-Aldrich), stained with GelCode Blue and sequenced by the Stanford PAN or University of California Molecular Structure Facility (Davis, CA) facilities.

Calcium mobilization assay

Cells were loaded for 1 h with 2 µM indo-1/AM dye (Molecular Probes) in culture medium, then washed with HBSS and resuspended at 107/ml in HBSS containing 0.1% BSA. Cytosolic calcium responses were determined using a Photon Technology International fluorometer, with excitation at 350 nm and dual emission at 400 and 490 nm. Alternatively, cells were loaded with 5 µg/ml fluo-4 AM dye (Molecular Probes), then washed and analyzed on a Fluorometric Imaging Plate Reader 384 (Molecular Devices), with 505 nm excitation and 530 nm emission.

Chemotaxis assay

L1.2-CCR1 transfectants, THP-1 cells, human monocytes, and human neutrophils were collected by centrifugation and resuspended in HBSS containing 0.1% BSA. Chemotaxis assays were performed in 96-well ChemoTx microplates (NeuroProbe) as follows. Chemokines were added to the lower wells (final volume, 29 µl), and 20 µl of cell suspension (5 x 106 cells/ml) was added to the polycarbonate filter (3-µm pore size for neutrophils, 5 µm for the other three cell types). After incubation at 37°C in the presence of 5% CO2 for 1 h (neutrophils), 90 min (monocytes), or 2 h (THP-1 and L1.2-CCR1), the filters were removed. Cells that migrated into the lower chamber were quantified by using the CyQuant cell proliferation assay kit (Molecular Probes) and analyzed with a Tecan fluorometer (excitation at 480 nm, emission at 530 nm). Data were analyzed and plotted in arbitrary units of fluorescence using PRISM (GraphPad).

Radiolabeled ligand binding assay

THP-1 cells (3 x 105/well) were mixed with dilutions of unlabeled chemokine (final concentration, 1 pM to 1 µM) and 0.025 µCi/well 125I-labeled MIP-1{alpha} (PerkinElmer) in a total volume of 200 µl and agitated at 4°C for 3 h. Levels of cell-bound radioactivity were determined by harvesting the cells on polyethylenimine-treated GF/B glass filters (PerkinElmer) using a cell harvester (PerkinElmer), washing the filters twice with buffer (25 mM HEPES, 500 mM NaCl, 1 mM CaCl2, and 5 mM MgCl2, adjusted to pH 7.1), and measuring the amount of 125I bound to each filter (in cpm) with a TopCount scintillation counter (PerkinElmer).

ELISA

Serial 10-fold dilutions of human synovial fluids were analyzed for levels of CCL3/MIP-1{alpha} and CCL5/RANTES with commercial sandwich ELISA kits (BD Biosciences) according to the manufacturer’s protocol. The fluids were also analyzed for human CCL15/MIP-1{delta} and CCL23/CK{beta}8 by sandwich ELISA using Abs from R&D Systems. First, total CCL15/MIP-1{delta} and CCL23/CK{beta}8 levels were determined using Ab pairs capable of recognizing both full-length and N-terminally truncated forms of each chemokine: capture mAb MAB363 and detector Ab BAF363 were used for CCL15/MIP-1{delta}, whereas capture mAb MAB371 and detector Ab BAF508 were used for CCL23/CK{beta}8. To determine whether the CCL15/MIP-1{delta} and CCL23/CK{beta}8 detected were full-length, the capture mAbs were replaced with anti-CCL23 mAb clone 69510 (a gift from R&D Systems), which is specific for the N-terminal domain that is nearly identical between the two chemokines. As such, this mAb recognizes the full-length forms, but not the N-terminally truncated forms of the two chemokines. Quantitation of the chemokines was determined using standard curves of full-length rCCL15/MIP-1{delta} and CCL23/CK{beta}8 (for the full-length chemokine-specific assays) or N-terminally truncated CCL15{Delta}24/LKN-1 and CCL23{Delta}24/MPIF-1 (for the total chemokine assays). The CCL15/MIP-1{delta} and CCL23/CK{beta}8 detected in the fluids were not factors in the functional analyses of the in vitro digests, because the synovial fluids were diluted 10-fold in the digests, and the digests were then diluted at least 100-fold in the functional assays.


   Results
Top
 Abstract
 Introduction
 Materials and Methods
 Results
Discussion
 Disclosures
 References
 
rCCL15/MIP-1{delta} was tested for its ability to be cleaved by proteases and physiological fluids associated with inflammation. The chemokine was incubated for 1 or 18 h with recombinant mast cell chymase, purified neutrophil cathepsin G, purified neutrophil elastase, activated neutrophil-conditioned medium from two donors, or synovial fluid from 10 patients with rheumatoid arthritis or three patients with sports-related knee injuries. SDS-PAGE analysis of the digests indicated that nearly all the proteases and fluids cleaved CCL15/MIP-1{delta}, generating truncated forms ~2–3 kDa smaller than the parental chemokine (Fig. 1A). The truncated forms exhibited electrophoretic mobilities similar to rCCL15/MIP-1{delta} lacking the N-terminal 24 residues (CCL15{Delta}24/LKN-1; Fig. 1A). N-terminal sequencing of the truncated forms indicated that the proteases and fluids partially or completely removed the CCL15 N-terminal domain, leaving three to 10 residues upstream of the conserved CC motif (Fig. 1B).



View larger version (40K):
[in this window]
[in a new window]
  		FIGURE 1. Proinflammatory proteases and fluids digest and activate the human NC6 chemokine CCL15/MIP-1{delta}. CCL15/MIP-1{delta} was incubated for 1 or 18 h with recombinant mast cell chymase, purified neutrophil cathepsin G, purified neutrophil elastase, activated neutrophil-conditioned medium from two donors (PMN sup 1 and PMN sup 2), synovial fluids from three patients with sports-related knee injuries (synovial, synovial 2, and synovial 3) and synovial fluids from 10 patients with rheumatoid arthritis (RA1 to RA10). A, Analysis by SDS-PAGE. Portions of the digests were subjected to SDS-PAGE, then the gels (left and right panels) or a polyvinylidene difluoride filter after electroblotting (middle panel) was stained with Coomassie Blue. Digests lacking chemokine (PMN sup alone and synovial alone; same dilutions as the digests containing chemokine) and rCCL15{Delta}24/LKN-1 are shown for comparison. B, N-terminal sequence analysis. N-terminal sequences of some of the truncated CCL15/MIP-1{delta} forms were determined by N-terminal Edman sequencing after SDS-PAGE and electroblotting. Residues shown in red are encoded by the additional exon. C and D, Calcium mobilization assay. Murine L1.2 cells expressing human CCR1 were loaded with a calcium-sensitive fluorescent dye, then treated with a portion of the digests and analyzed for fluorescence over time. C, The two panels shown are from separate experiments. Digests lacking chemokine (same dilutions as the digests containing chemokine) and rCCL15{Delta}24/LKN-1 are shown for comparison. D, Each trace’s peak level of fluorescence is plotted. E, Chemotaxis assay. Dilutions of CCL15/MIP-1{delta}, CCL15{Delta}24/LKN-1, and either three of the CCL15/MIP-1{delta} digests (left panel) or CCL3/MIP-1{alpha} and CCL5/RANTES (right panel) were exposed to THP-1 cells for 2 h, after which the migrated cells were solubilized and quantified by DNA content. Mean peak values (in log [chemokine] M) are: left panel: CCL15, greater than –7; CCL15{Delta}24, –9.655 ± 0.155; CCL15 plus chymase, –9.406 ± 0.098; CCL15 plus synovial, –9.61 ± 0.145; CCL15 plus PMN sup 1, –8.297 ± 0.164; right panel: CCL3, –9.712 ± 0.084; CCL5, –9.423 ± 0.092; CCL15, greater than –7; CCL15D24, –10.19 ± 0.07.

 
To determine whether the truncated forms exhibited enhanced functional activities, the digests were subjected to several functional assays in vitro. First, the digests were analyzed for their ability to induce signaling in CCR1+ cells, as measured by changes in cytosolic calcium levels over time. At 10 nM, full-length CCL15/MIP-1{delta} induced little calcium mobilization in murine L1.2 cells stably expressing human CCR1, whereas rCCL15{Delta}24/LKN-1 induced a substantially greater response (Fig. 1, C and D). At 10 nM input chemokine, all the digests similarly mobilized a greater amount of calcium than full-length CCL15/MIP-1{delta}, in some cases even more than CCL15{Delta}24/LKN-1 (Fig. 1, C and D). Control digests lacking CCL15/MIP-1{delta} did not induce calcium mobilization, indicating that the signaling activity of the digests derived from the truncated chemokines and not the proteases or fluids themselves (Fig. 1, C and D).

The truncated forms were also analyzed for their chemoattractant activity for CCR1-bearing cells in vitro. Human THP-1 cells were used because of their high migratory potential. Full-length CCL15/MIP-1{delta} was a relatively weak chemoattractant for THP-1 cells (EC50, 50 nM), whereas CCL15{Delta}24/LKN-1 was much more potent (EC50, 60 pM; Fig. 1E). The digests were similarly potent, exhibiting EC50 values of 50 pM (chymase), 60 pM (synovial fluid), and 250 pM (PMN sup 1; Fig. 1E). Control digests lacking CCL15/MIP-1{delta} did not induce THP-1 migration, indicating that the chemotactic activity of the digests was due to the truncated chemokines and not the proteases or fluids themselves (our unpublished observations). Chemotaxis assays using CCL3/MIP-1{alpha} or CCL5/RANTES indicated that these traditional CCR1 ligands were ~3-fold less potent than CCL15{Delta}24/LKN-1 (Fig. 1E).

Because the proinflammatory proteases and fluids rendered CCL15/MIP-1{delta} even more potent than CCL3/MIP-1{alpha} and CCL5/RANTES, we tested the ability of the CCL15/MIP-1{delta} digests to function on human neutrophils, which are responsive to CCL15{Delta}24/LKN-1, but not to CCL3/MIP-1{alpha} or CCL5/RANTES (Fig. 2A). At 30–50 nM, the CCL15/MIP-1{delta} digests induced calcium mobilization in neutrophils, in some cases as much as that induced by CCL15{Delta}24/LKN-1 (Fig. 2B). Desensitization of the neutrophils with high concentrations of CCL3/MIP-1{alpha} impaired the ability of the cells to respond to the CCL15/MIP-1{delta} digests (Fig. 2C), indicating that the cleaved forms of CCL15/MIP-1{delta} signaled through CCR1 in the neutrophils. Moreover, addition of a small-molecule antagonist of CCR1 to the neutrophils 20 s before addition of the digests resulted in complete abrogation of calcium mobilization (data not shown), confirming that the N-terminally truncated forms of CCL15/MIP-1{delta} signaled through CCR1 in the neutrophils.



View larger version (29K):
[in this window]
[in a new window]
  		FIGURE 2. Human neutrophils respond to CCL15/MIP-1{delta} after truncation by proinflammatory proteases and fluids, but not to CCL3/MIP-1{alpha} or CCL5/RANTES. A, Calcium mobilization assay. Freshly isolated human neutrophils were loaded with a calcium-sensitive fluorescent dye and exposed to dilutions of CCL15{Delta}24/LKN-1, CCL3/MIP-1{alpha}, or CCL5/RANTES. Changes in fluorescence were measured over time, and peak fluorescence levels were plotted vs chemokine concentration. B, Calcium mobilization assay. Freshly isolated human neutrophils were loaded with a calcium-sensitive fluorescent dye and exposed to CCL15{Delta}24/LKN-1 or the CCL15/MIP-1{delta} digests at 30 nM (left panel) or 50 nM (right panel). C, Calcium mobilization assay. Freshly isolated human neutrophils from two donors were loaded with a calcium-sensitive fluorescent dye and exposed to the CCL15/MIP-1{delta} digests ~20 s after exposure to an excess of CCL3/MIP-1{alpha} or, as a control, an equal volume of HBSS buffer. B and C, Changes in fluorescence are depicted over time, and control digests lacking chemokine are shown for comparison.

 
Because CCL15/MIP-1{delta} was consistently truncated and activated by the proinflammatory proteases and fluids, the other NC6 chemokines, CCL6/C10/MRP-1, CCL9/MIP-1{gamma}/MRP-2, and CCL23/CK{beta}8/MPIF-1 (Fig. 3), were similarly tested for truncation and activation. The three other NC6 chemokines were truncated by ~2–4 kDa by the proteases and fluids (Fig. 4A), and N-terminal sequencing of the truncated forms indicated that their N-terminal domains were mostly or completely removed (Fig. 4B). At 10 nM input chemokine, the digests were uniformly active for calcium mobilization in L1.2-CCR1 cells, whereas the undigested parental chemokines were either not active or weakly active (Fig. 4C). Control digests lacking the chemokines did not induce calcium mobilization, as seen before (Fig. 1C). Three-point titrations of selected CCL6/C10 and CCL9/MIP-1{gamma} digests in the L1.2-CCR1 chemotaxis assay indicated that the truncated forms stimulated chemotaxis with greater potency than the full-length chemokines (Fig. 4D). A more extensive titration of the CCL23/CK{beta}8 digests on THP-1 cells indicated that chymase decreased the EC50 50-fold, from 2.5 nM to 50 pM, whereas PMN sup 1 decreased the EC50 to 150 pM, and synovial fluid decreased the EC50 to 250 pM (Fig. 4E). rCCL23/CK{beta}8 lacking the N-terminal 24 residues (CCL23{Delta}24/MPIF-1) exhibited an EC50 of 90 pM. As before, control digests lacking CCL6, CCL9, and CCL23 did not chemoattract L1.2-CCR1 or THP-1 cells, indicating that the chemotactic activity of the chemokine digests was due to the truncated chemokines and not to the proteases or fluids themselves (Fig. 4D).



View larger version (10K):
[in this window]
[in a new window]
  		FIGURE 3. Protein sequence alignment of the N-terminal ends of the four NC6 chemokines: murine CCL6/C10/MRP-1, murine CCL9/MIP-1{gamma}/MRP-2, human CCL15/MIP-1{delta}/LKN-1/HCC-2, and human CCL23/CK{beta}8/MPIF-1. The 21-residue leader sequences are not shown. Numbering for CCL6 is shown at the top; numbering for CCL15 and CCL23 is shown at the bottom. The separately encoded N-terminal domains are shown in bold, and the CC motif is boxed. The genomic exon/intron organization of CCL9 has not been determined.

 


View larger version (52K):
[in this window]
[in a new window]
  		FIGURE 4. Proinflammatory proteases and fluids digest the NC6 chemokines CCL6/C10, CCL9/MIP-1{gamma}, and CCL23/CK{beta}8. Each chemokine was treated for 15 min, 1 h, or 18 h with the proteases and fluids described in Fig. 1. A–C, CCL6/C10 is shown in the left panel, CCL9/MIP-1{gamma} is shown in the middle panel, and CCL23/CK{beta}8 is shown in the right panel. A, Analysis by SDS-PAGE. Portions of the digests were subjected to SDS-PAGE, with subsequent Coomassie Blue staining of the gels. Digests lacking chemokine (PMN sup alone and synovial alone; same dilutions as the digests containing chemokine) are shown for comparison. B, N-terminal sequence analysis. N-terminal sequences of some of the truncated forms were determined by N-terminal Edman sequencing after SDS-PAGE and electroblotting. Residues shown in red are encoded by the additional exon (not yet defined for CCL9/MIP-1{gamma}). C, Calcium mobilization assay. Murine L1.2 cells expressing human CCR1 were loaded with a calcium-sensitive fluorescent dye, then treated with a portion of the digests and analyzed for fluorescence over time. rCCL23{Delta}24/MPIF-1 and digests lacking chemokine are shown for comparison. The two panels shown for each chemokine are from separate experiments. D and E, Chemotaxis assay. Dilutions of digests were tested for the ability to chemoattract L1.2-CCR1 or THP-1 cells in vitro. D, L1.2-CCR1 cells were exposed to selected CCL6/C10, CCL9/MIP-1{gamma}, or no-chemokine digests at 0.5 nM (blue bars), 5 nM (purple bars), or 50 nM (red bars) for 2 h, after which the relative amounts of migration were measured by DNA content. The p values (asterisks) are 0.002 for 0.5 nM CCL6 vs CCL6 plus PMN sup 1, <0.001 for 0.5 nM CCL9 vs CCL9 plus PMN sup 1, and <0.001 for 5 nM CCL9 vs CCL9 plus synovial. E, THP-1 cells were exposed to multiple dilutions of the CCL23/CK{beta}8 digests for 2 h, after which the migrated cells were solubilized and quantified by DNA content. Mean peak values (in log [chemokine] M) are: CCL23, –7.894 ± 0.18; CCL23{Delta}24, –9.205 ± 0.115; CCL23 plus chymase, –9.665 ± 0.159; CCL23 plus synovial, –8.703 ± 0.163; CCL15 plus PMN sup 1, –9.131 ± 0.187.

 
To determine whether proteolytic cleavage increased chemokine potency in primary human cells, CCL6/C10 was chosen because, of the four NC6 chemokines, it is the least potent on human monocytes and monocyte-derived immature dendritic cells (our unpublished observations). CCL6/C10, which was unable to induce calcium mobilization in monocytes even at 100 nM, mobilized calcium at that concentration after digestion with chymase, cathepsin G, elastase, or synovial fluid (Fig. 5A). CCL6/C10 also stimulated chemotaxis of monocytes at 200 nM after digestion with chymase, cathepsin G, or elastase (Fig. 5B). Digestion of CCL6/C10 with synovial fluid resulted in a dramatic increase in potency, with the most migration occurring at 2 nM (Fig. 5B). CCL6/C10 digests with chymase, cathepsin G, elastase, synovial fluid, or PMN sup 1 were also more efficacious than full-length CCL6/C10 for calcium mobilization in immature dendritic cells derived from monocytes (Fig. 5C).



View larger version (27K):
[in this window]
[in a new window]
  		FIGURE 5. Human monocytes and dendritic cells respond to CCL6/C10 after N-terminal truncation by proinflammatory proteases and fluids. A, Calcium mobilization assay. Freshly isolated human monocytes were loaded with a calcium-sensitive fluorescent dye, then exposed to the CCL6/C10 digests at 100 nM and analyzed for fluorescence over time. rCCL15{Delta}24/LKN-1 is shown for comparison. B, Chemotaxis assay. Freshly isolated monocytes were exposed to the CCL6/C10 digests at 2 nM ({square}), 20 nM ({cjs2108}), or 200 nM ({blacksquare}) for 90 min, after which the migrated cells were solubilized and quantified by DNA content. The p values (asterisks) are 0.004 for 2 nM CCL6 vs CCL6 plus synovial, 0.001 for 200 nM CCL6 vs CCL6 plus elastase, and <0.001 for 200 nM CCL6 vs CCL6 plus cathepsin G. C, Calcium mobilization assay. Immature monocyte-derived dendritic cells were loaded with a calcium-sensitive fluorescent dye, then exposed to the CCL6/C10 digests at 25 nM and analyzed for fluorescence over time. rCCL15{Delta}24/LKN-1 is shown for comparison.

 
To determine whether the increased potency exhibited by the cleaved forms of CCL15/MIP-{delta} and CCL23/CK{beta}8 were due to increased CCR1 binding, the cleaved forms were compared with the full-length forms as well as CCL3/MIP-1{alpha} in a radiolabeled ligand binding assay (Fig. 6). CCL15{Delta}24/LKN-1 exhibited a >3000-fold increase in binding over full-length CCL15/MIP-1{delta} (IC50, 0.1 vs 360 nM), whereas CCL23{Delta}24/MPIF-1 exhibited a 20-fold increase in binding over its parent chemokine (IC50, 0.6 vs 12 nM). For comparison, CCL3/MIP-1{alpha} exhibited an IC50 of 5 nM. The increased potency for binding CCR1 exhibited by the cleaved forms over the full-length forms of CCL15/MIP-{delta} and CCL23/CK{beta}8 correlated well with the increased potency for CCR1-mediated migration (Figs. 1 and 4), indicating that the latter is primarily due to increased levels of receptor binding and not to increased efficiency of ligand-mediated signaling.



View larger version (19K):
[in this window]
[in a new window]
  		FIGURE 6. N-terminally truncated forms of NC6 chemokines CCL15/MIP-1{delta} and CCL23/CK{beta}8 possess enhanced binding to CCR1. Recombinant CCL15/MIP-1{delta}, CCL15{Delta}24/LKN-1, CCL23/CK{beta}8, CCL23{Delta}24/MPIF-1, and CCL3/MIP-1{alpha} were analyzed for their ability to compete with radiolabeled CCL3/MIP-1{alpha} for binding to THP-1 cells as indicated in Materials and Methods.

 
To determine whether the chemokine-activating ability of the proinflammatory proteases and fluids was specific for the NC6 chemokines, three non-NC6 chemokines, CCL3/MIP-1{alpha}, CCL5/RANTES, and CCL25/TECK, were tested with a subset of the proteases and fluids. CCL3/MIP-1{alpha} and CCL5/RANTES were not visibly truncated by the two RA synovial fluids analyzed, whereas chymase initially truncated a portion of these two chemokines by ~2 kDa (Fig. 7A). However, in a THP-1 chemotaxis assay, each chemokine was at least 10-fold less potent after digestion with either RA fluid or chymase (Fig. 7B). CCL25/TECK, which has the longest C-terminal tail of the {beta}-chemokines, was rapidly cleaved and inactivated for signaling through CCR9 by all proteases and fluids tested (Fig. 7, A and C).



View larger version (39K):
[in this window]
[in a new window]
  		FIGURE 7. Proinflammatory proteases and fluids do not activate the non-NC6 chemokines CCL3/MIP-1{alpha}, CCL5/RANTES, and CCL25/TECK. Each chemokine was treated for varying times with selected proteases and fluids as described in Fig. 1. A, Analysis by SDS-PAGE. Portions of the digests were subjected to SDS-PAGE, with subsequent Coomassie Blue staining of the gels. B, Chemotaxis assay. THP-1 cells were exposed to titrations of the CCL3/MIP-1{alpha} and CCL5/RANTES digests for 2 h, after which the migrated cells were solubilized and quantified by DNA content. C, Calcium mobilization assay. Molt4 cells were loaded with a calcium-sensitive fluorescent dye, then exposed to the CCL25/TECK digests at 1 nM and analyzed for fluorescence over time.

 
To assess whether NC6 chemokines with N-terminal truncations exist in vivo, the panel of 13 synovial fluids was analyzed by sandwich ELISA. For CCL15/MIP-1{delta}, an assay recognizing full-length, but not N-terminally truncated, CCL15/MIP-1{delta} detected protein in none of the 13 synovial fluids; comparison with a standard curve of CCL15/MIP-1{delta} defined the limit of detection as 90 pM (Table I). In contrast, an assay recognizing both full-length and N-terminally truncated CCL15/MIP-1{delta} detected protein in all 13 fluids; comparison with a standard curve of CCL15{Delta}24/LKN-1 indicated that the synovial fluids contained 130–900 pM (Table I; limit of quantitation, 120 pM). Similarly, an assay recognizing full-length, but not N-terminally truncated, CCL23/CK{beta}8 detected protein in none of the 13 synovial fluids; comparison with a standard curve of CCL23/CK{beta}8 defined the limit of detection as 80 pM (Table I). An assay recognizing both full-length and N-terminally truncated CCL23/CK{beta}8 detected protein in 12 of the 13 fluids. Comparison with a standard curve of CCL23{Delta}24/MPIF-1 indicated that these 12 synovial fluids contained 400–950 pM (Table I; limit of quantitation, 220 pM). However, the possibility that the synovial fluids contained small amounts of full-length CCL15/MIP-1{delta} (up to 90 pM) and/or CCL23/CK{beta}8 (up to 80 pM) makes it difficult to quantify precisely the levels of N-terminally truncated CCL15 or CCL23. In contrast, commercial ELISA kits specific for human CCL3/MIP-1{alpha}, CCL5/RANTES, and CCL7/MCP-3 detected only low levels (20–120 pM) of chemokine and in only a subset of the synovial fluids analyzed (Table I).


View this table:
[in this window]
[in a new window]
  		Table I. Detection of CCR1 ligands in synovial fluidsa

 

   Discussion
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
Disclosures
 References
 
In this study we have demonstrated that the N-terminal domain unique to the NC6 chemokines, murine CCL6/C10 and CCL9/MIP-1{gamma}, human CCL15/MIP-1{delta}, and CCL23/CK{beta}8, is readily removed by proteases associated with human inflammatory responses. Recombinant mast cell chymase, purified neutrophil cathepsin G, purified neutrophil elastase, conditioned medium from activated neutrophils, and synovial fluids from patients with rheumatoid arthritis or sports-related knee injuries all fully or partially removed the N-terminal domain of each of the four NC6 chemokines in vitro. The site of cleavage varied from three to 14 residues upstream of the dicysteine motif. Each truncated chemokine was relatively resistant to further digestion by the proteases despite the presence of additional potential cleavage sites. Presumably, these additional sites are inaccessible to the proteases.

As a result of proteolytic removal of the N-terminal domain, all four NC6 chemokines became substantially more potent ligands for CCR1, as measured by receptor binding, calcium mobilization, and cell migration in vitro. We have designated the activated state of truncated NC6 chemokines as the NC6* state. Cleavage of CCL15/MIP-1{delta} by chymase or synovial fluid increased chemokine potency in THP-1 cell migration ~1000-fold, to an EC50 of 50–60 pM, similar to rCCL15{Delta}24/LKN-1, which lacks the N-terminal domain altogether. Cleavage of CCL23/CK{beta}8 by chymase increased that chemokine’s potency to 50 pM as well. These potencies are above those of the CCR1 ligands that have been historically better characterized, CCL3/MIP-1{alpha} and CCL5/RANTES, which exhibit EC50 values of ~500 pM. Protease incubation with CCL3/MIP-1{alpha} and CCL5/RANTES resulted in decreases in functional potency, presumably because neither of these two chemokines possesses an inhibitory N-terminal domain. The N-terminally truncated (NC6*) forms of CCL15/MIP-1{delta} and CCL23/CK{beta}8 are the most potent CCR1 ligands known.

Due to its potency, the NC6* form of CCL15/MIP-1{delta} was functional on human neutrophils, which are poorly responsive to CCL3/MIP-1{alpha} (14, 15) or CCL5/RANTES (14) in vitro. The specificity of CCR1 use on the neutrophils was confirmed by pretreating the cells with a CCR1-specific, small-molecule antagonist or with high concentrations of CCL3/MIP-1{alpha}. Although CCL3/MIP-1{alpha} did not induce calcium mobilization on its own, it partially or completely desensitized the cells to subsequent exposure to the NC6* forms of CCL15/MIP-1{delta}. CCL3/MIP-1{alpha} also signals through CCR5, but neutrophils do not express CCR5. Interestingly, neutrophils from half (four of eight) of the donors tested exhibited markedly reduced responses to CCL15{Delta}24/LKN-1, although responses to CXCL8/IL-8 were nearly uniform for all donors. The explanation for this variation in CCL15{Delta}24/LKN-1 responsiveness is currently being studied.

Because digest mixtures, not purified cleavage fragments, were applied to the cells in our studies, it is possible that the proteases altered the cells, rendering them more responsive to the chemokines. However, because calcium mobilization was observed within 5 s after addition of the digests, any such modification of the cells would have had to occur very rapidly. Moreover, because recombinant chemokines CCL15{Delta}24 and CCL23{Delta}24, lacking N-terminal domains, exhibited similar potencies in the absence of proteases, it is unlikely that protease-mediated cellular changes contributed substantially to the results.

Proteases have been reported to both activate and inactivate chemokine function. Chemokine activation after proteolytic removal of N-terminal residues has been described for two other CCR1 ligands, CCL14/HCC-1 (16, 17) and the MIP-1{alpha} isoform LD78{beta} (18), as well as for CXC chemokines CXCL1–3, -5, and -8 (19, 20, 21, 22, 23, 24). However, none of these chemokines possesses separately encoded, extended N-terminal domains, and all truncations were relatively small (<10 aa residues removed). Interestingly, the CXCR2 ligand CXCL7/neutrophil-activating protein-2 is generated by proteolytic removal of the N-terminal 11 aa of {beta}-thromboglobulin (25), which itself is inactive on CXCR2. A synthetic form of neutrophil-activating protein-2 containing five additional N-terminal residues was shown to be inactive in vitro due to folding of the extended N terminus over the glutamic acid-leucine-arginine region near the dicysteine motif (26).

Not surprisingly, proteolytic removal of N-terminal residues has also been shown to inactivate CC and CXC chemokines (27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38). In many cases, these truncated chemokines were still able to bind their receptors and, as a result, functioned as antagonists in chemotaxis assays in vitro (27, 30, 31, 32, 33, 34, 36) and exhibited anti-inflammatory properties in vivo (27, 32).

It is interesting that in the absence of exogenously added chemokines, certain proinflammatory proteases have been shown to induce leukocyte chemotaxis in vitro and in vivo. Injection of human chymase or tryptase into guinea pig skin or mouse peritoneal cavity resulted in substantial neutrophil and eosinophil recruitment within 3 h (39, 40). Injection of human chymase into mouse ear also resulted in polymorphonuclear cell recruitment (41, 42). Moreover, a chymase inhibitor significantly impaired cell recruitment in several experimentally induced and natural dermatitis models, indicating that chymase plays a role in dermal inflammatory reactions (41, 42, 43, 44). These in vivo studies indicate that either chymase activates a resident, dormant chemokine, or that chymase itself is chemotactic. Although chymase was not found to be chemotactic in our study, two groups reported that this enzyme was chemotactic for human leukocytes in vitro (41, 42, 45). However, enzymatic activity was required for chemoattraction in each of these studies, raising the possibility that the actual chemoattractant might have been a chymase-derived cleavage fragment of an inactive chemokine secreted by the cells. Chymase can cleave endothelins, producing 21- and 31-residue vasoactive peptides that are chemotactic for human monocytes, neutrophils (46), and macrophages (47). With regard to other proteases, neutrophil protease cathepsin G has also been shown to be chemotactic for human neutrophils, monocytes, and macrophages in a manner likewise dependent on enzyme activity (48, 49). Injection of cathepsin G into mouse skin resulted in neutrophil and macrophage recruitment (49). In addition, CD13/endopeptidase N, an ectoenzyme and T cell chemoattractant (50), was observed at elevated levels on alveolar macrophages in two separate rat models of airway T cell inflammation (50, 51). CD13 was also observed at elevated levels on synovial fibroblasts and in synovial fluid from patients with rheumatoid arthritis (52).

Our demonstration that NC6 chemokines are activated to NC6* states by proinflammatory proteases in vitro raises the distinct possibility that this type of regulation also occurs in vivo. In mice, CCL9/MIP-1{gamma} mRNA is expressed constitutively in a wide variety of tissues in the absence of exogenous stimuli and is also expressed in murine myeloid cell lines (53, 54, 55), in contrast to CCL3/MIP-1{alpha} mRNA, which is expressed only in select tissues and only after the addition of exogenous stimuli such as LPS (53). CCL9/MIP-1{gamma} protein has also been detected in multiple tissues (53) and in a Langerhans cell line (7), and can reach 1 µg/ml (90 nM) in normal murine serum (53). CCL6/C10 mRNA is expressed in normal peritoneal cells (56), and full-length CCL6/C10 protein is expressed in normal lung macrophages, smooth muscle cells, and fibroblasts (57). The constitutive expression of CCL9/MIP-1{gamma} and CCL6/C10 suggests that NC6 chemokines might be present during the very first steps of inflammation, when mast cells or neutrophils degranulate. In fact, the full-length NC6 chemokines could serve as inhibitors of CCR1+ cell migration in the absence of inflammation, although we observed that full-length NC6 chemokines possess weak CCR1 binding affinity in vitro. When an inflammatory event is triggered, released proteases might activate CCL6/C10 or CCL9/MIP-1{gamma}, setting up an immediate gradient of an extremely potent CCR1 ligand. However, no studies have been performed to determine whether this phenomenon occurs in vivo. In the only published study of CCL9/MIP-1{gamma} function in vivo, the chemokine was implicated in CD11b+ dendritic cell recruitment to murine Peyer’s patches (58). In vivo studies of the function of CCL6/C10 focus on mRNA and protein induction in murine inflammation models; in some models, the induction occurs early and is required for leukocyte recruitment (57, 59, 60), whereas in other models, CCL6/C10 is induced late and is required for resolution of inflammation (56, 61). In addition, in these models only the full-length chemokine was detected, because the polyclonal anti-C10 antiserum used did not recognize N-terminally truncated forms (9), presumably due to the high density of charged amino acids in the N-terminal domain.

In humans, no studies have been published that demonstrate CCL15/MIP-1{delta} or CCL23/CK{beta}8 protein expression in vivo. We now show that both CCL15/MIP-1{delta} and CCL23/CK{beta}8 were present in nearly all synovial fluid samples studied. (The CCL15/MIP-1{delta} and CCL23/CK{beta}8 present in the fluids were not factors in the functional analyses of the in vitro digests, because the synovial fluids were diluted 10-fold in the digests, and then the digests were diluted at least 100-fold in the functional assays.) Using Ab pairs that can discriminate between full-length and N-terminally truncated chemokines, we observed that most (if not all) of each chemokine is N-terminally truncated and present at concentrations (140–950 pM) well above those required to elicit chemotaxis of CCR1-bearing cells in vitro. In contrast, concentrations of CCL3/MIP-1{alpha} and CCL5/RANTES in the fluids were always <120 pM and often below 20 pM, far below the concentration required for chemotaxis in vitro. The presence of substantially more CCL15/MIP-1{delta} and CCL23/CK{beta}8 than CCL3/MIP-1{alpha} and CCL5/RANTES in the synovial fluids is consistent with our observation that the former two chemokines are activated by the synovial fluids in vitro, whereas the latter two chemokines are inactivated. These results raise the possibility that in inflamed synovial tissue, where CCR1 is thought to play a critical role in leukocyte infiltration (62), N-terminally truncated CCL15/MIP-1{delta} and CCL23/CK{beta}8, rather than CCL3/MIP-1{alpha} or CCL5/RANTES, actively recruit CCR1-bearing monocytes and neutrophils. In pilot experiments in vitro, we have observed that the synovial fluids chemoattract THP-1 cells in a CCR1-dependent manner: small-molecule antagonists specific for CCR1, but not those specific for CCR2 or CXCR4, completely blocked chemotaxis. However, mAbs specific for CCL3/MIP-1{alpha}, CCL5/RANTES, CCL15/MIP-1{delta}, and CCL23/CK{beta}8 were not able to block chemotaxis of THP-1 cells to the synovial fluids, even when all four mAbs were pooled. This result suggests that the mAbs are not neutralizing for the natural (i.e., nonrecombinant) forms of the NC6 chemokines.


   Acknowledgments
 
Many thanks to Kevin W. Moore for his critical reading of this manuscript.


   Disclosures
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 Disclosures
References
 
The authors have no financial conflict of interest.


   Footnotes
 
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

1 This work was supported by the National Institutes of Health, Cooperative Agreement U19AI56690. Back

2 R.D.B. and Z.M. contributed equally to this work. Back

3 Address correspondence and reprint requests to Dr. Robert D. Berahovich, ChemoCentryx, 850 Maude Avenue, Mountain View, CA 94043. E-mail address: rberahovich{at}chemocentryx.com Back

4 Abbreviations used in this paper: HCC, hemofiltrate CC chemokine; MRP, MIP-related protein; MPIF, myeloid progenitor inhibitory factor; LKN, leukotactin. Back

Received for publication October 28, 2004. Accepted for publication March 28, 2005.


   References
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 Disclosures
 References
 

  1. Berger, M. S., C. A. Kozak, A. Gabriel, M. B. Prystowsky. 1993. The gene for C10, a member of the {beta}-chemokine family, is located on mouse chromosome 11 and contains a novel second exon not found in other chemokines. DNA Cell Biol. 12: 839-847.[Medline]
  2. Pardigol, A., U. Forssmann, H. D. Zucht, P. Loetscher, P. Schulz-Knappe, M. Baggiolini, W. G. Forssmann, H. J. Magert. 1998. HCC-2, a human chemokine: gene structure, expression pattern, and biological activity. Proc. Natl. Acad. Sci. USA 95: 6308-6313.[Abstract/Free Full Text]
  3. Youn, B. S., S. M. Zhang, H. E. Broxmeyer, S. Cooper, K. Antol, M. Fraser, B. S. Kwon. 1998. Characterization of CK{beta}8 and CK{beta}8-1: two alternatively spliced forms of human {beta}-chemokine, chemoattractants for neutrophils, monocytes, and lymphocytes, and potent agonists at CC chemokine receptor 1. Blood 91: 3118-3126.[Abstract/Free Full Text]
  4. Rajarathnam, K., Y. Li, T. Rohrer, R. Gentz. 2001. Solution structure and dynamics of myeloid progenitor inhibitory factor-1 (MPIF-1), a novel monomeric CC chemokine. J. Biol. Chem. 276: 4909-4916.[Abstract/Free Full Text]
  5. Macphee, C. H., E. R. Appelbaum, K. Johanson, K. E. Moores, C. S. Imburgia, J. Fornwald, T. Berkhout, M. Brawner, P. H. Groot, K. O’Donnell, et al 1998. Identification of a truncated form of the CC chemokine CK{beta}-8 demonstrating greatly enhanced biological activity. J. Immunol. 161: 6273-6279.[Abstract/Free Full Text]
  6. Youn, B. S., S. M. Zhang, E. K. Lee, D. H. Park, H. E. Broxmeyer, P. M. Murphy, M. Locati, J. E. Pease, K. K. Kim, K. Antol, et al 1997. Molecular cloning of leukotactin-1: a novel human {beta}-chemokine, a chemoattractant for neutrophils, monocytes, and lymphocytes, and a potent agonist at CC chemokine receptors 1 and 3. J. Immunol. 159: 5201-5205.[Abstract]
  7. Mohamadzadeh, M., A. N. Poltorak, P. R. Bergstressor, B. Beutler, A. Takashima. 1996. Dendritic cells produce macrophage inflammatory protein-1{gamma}, a new member of the CC chemokine family. J. Immunol. 156: 3102-3106.[Abstract]
  8. Wang, W., K. B. Bacon, E. R. Oldham, T. J. Schall. 1998. Molecular cloning and functional characterization of human MIP-1{delta}, a new C-C chemokine related to mouse CCF-18 and C10. J. Clin. Immunol. 18: 214-222.[Medline]
  9. Berger, M. S., D. D. Taub, A. Orlofsky, T. R. Kleyman, B. Coupaye-Gerard, D. Eisner, S. A. Cohen. 1996. The chemokine C10: immunological and functional analysis of the sequence encoded by the novel second exon. Cytokine 8: 439-447.[Medline]
  10. Berkhout, T. A., J. Gohil, P. Gonzalez, C. L. Nicols, K. E. Moores, C. H. Macphee, J. R. White, P. H. Groot. 2000. Selective binding of the truncated form of the chemokine CK{beta}8 (25–99) to CC chemokine receptor 1 (CCR1). Biochem. Pharmacol. 59: 591-596.[Medline]
  11. Lee, J. K., E. H. Lee, Y. P. Yun, K. Kim, K. Kwack, D. S. Na, B. S. Kwon, C. K. Lee. 2002. Truncation of NH2-terminal amino acid residues increases agonistic potency of leukotactin-1 on CC chemokine receptors 1 and 3. J. Biol. Chem. 277: 14757-14763.[Abstract/Free Full Text]
  12. Nardelli, B., H. L. Tiffany, G. W. Bong, P. A. Yourey, D. K. Morahan, Y. Li, P. M. Murphy, R. F. Alderson. 1999. Characterization of the signal transduction pathway activated in human monocytes and dendritic cells by MPIF-1, a specific ligand for CC chemokine receptor 1. J. Immunol. 162: 435-444.[Abstract/Free Full Text]
  13. Witko-Sarsat, V., P. Rieu, B. Descamps-Latscha, P. Lesavre, L. Halbwachs-Mecarelli. 2000. Neutrophils: molecules, functions and pathophysiological aspects. Lab. Invest. 80: 617-653.[Medline]
  14. Cheng, S. S., J. J. Lai, N. W. Lukacs, S. L. Kunkel. 2001. Granulocyte-macrophage colony stimulating factor up-regulates CCR1 in human neutrophils. J. Immunol. 166: 1178-1184.[Abstract/Free Full Text]
  15. Zhang, S., B. S. Youn, J. L. Gao, P. M. Murphy, B. S. Kwon. 1999. Differential effects of leukotactin-1 and macrophage inflammatory protein-1{alpha} on neutrophils mediated by CCR1. J. Immunol. 162: 4938-4942.[Abstract/Free Full Text]
  16. Detheux, M., L. Standker, J. Vakili, J. Munch, U. Forssmann, K. Adermann, S. Pohlmann, G. Vassart, F. Kirchhoff, M. Parmentier, et al 2000. Natural proteolytic processing of hemofiltrate CC chemokine 1 generates a potent CC chemokine receptor (CCR)1 and CCR5 agonist with anti-HIV properties. J. Exp. Med. 192: 1501-1508.[Abstract/Free Full Text]
  17. Vakili, J., L. Standker, M. Detheux, G. Vassart, W. G. Forssmann, M. Parmentier. 2001. Urokinase plasminogen activator and plasmin efficiently convert hemofiltrate CC chemokine 1 into its active [9–74] processed variant. J. Immunol. 167: 3406-3413.[Abstract/Free Full Text]
  18. Proost, P., P. Menten, S. Struyf, E. Schutyser, I. De Meester, J. Van Damme. 2000. Cleavage by CD26/dipeptidyl peptidase IV converts the chemokine LD78{beta} into a most efficient monocyte attractant and CCR1 agonist. Blood 96: 1674-1680.[Abstract/Free Full Text]
  19. Hebert, C. A., F. W. Luscinskas, J. M. Kiely, E. A. Luis, W. C. Darbonne, G. L. Bennett, C. C. Liu, M. S. Obin, M. A. Gimbrone, Jr, J. B. Baker. 1990. Endothelial and leukocyte forms of IL-8. Conversion by thrombin and interactions with neutrophils. J. Immunol. 145: 3033-3040.[Abstract]
  20. Nourshargh, S., J. A. Perkins, H. J. Showell, K. Matsushima, T. J. Williams, P. D. Collins. 1992. A comparative study of the neutrophil stimulatory activity in vitro and pro-inflammatory properties in vivo of 72 amino acid and 77 amino acid IL-8. J. Immunol. 148: 106-111.[Abstract]
  21. Car, B. D., M. Baggiolini, A. Walz. 1991. Formation of neutrophil-activating peptide 2 from platelet-derived connective-tissue-activating peptide III by different tissue proteinases. Biochem. J. 275: 581-584.
  22. Wuyts, A., C. Govaerts, S. Struyf, J. P. Lenaerts, W. Put, R. Conings, P. Proost, J. Van Damme. 1999. Isolation of the CXC chemokines ENA-78, GRO{alpha} and GRO{gamma} from tumor cells and leukocytes reveals NH2-terminal heterogeneity: functional comparison of different natural isoforms. Eur. J. Biochem. 260: 421-429.[Medline]
  23. Nufer, O., M. Corbett, A. Walz. 1999. Amino-terminal processing of chemokine ENA-78 regulates biological activity. Biochemistry 38: 636-642.[Medline]
  24. King, A. G., K. Johanson, C. L. Frey, P. L. DeMarsh, J. R. White, P. McDevitt, D. McNulty, J. Balcarek, Z. L. Jonak, P. K. Bhatnagar, et al 2000. Identification of unique truncated KC/GRO{beta} chemokines with potent hematopoietic and anti-infective activities. J. Immunol. 164: 3774-3782.[Abstract/Free Full Text]
  25. Walz, A., M. Baggiolini. 1989. A novel cleavage product of {beta}-thromboglobulin formed in cultures of stimulated mononuclear cells activates human neutrophils. Biochem. Biophys. Res. Commun. 159: 969-975.[Medline]
  26. Malkowski, M. G., J. B. Lazar, P. H. Johnson, B. F. Edwards. 1997. The amino-terminal residues in the crystal structure of connective tissue activating peptide-III (des10) block the ELR chemotactic sequence. J. Mol. Biol. 266: 367-380.[Medline]
  27. McQuibban, G. A., J. H. Gong, E. M. Tam, C. A. McCulloch, I. Clark-Lewis, C. M. Overall. 2000. Inflammation dampened by gelatinase A cleavage of monocyte chemoattractant protein-3. Science 289: 1202-1206.[Abstract/Free Full Text]
  28. McQuibban, G. A., G. S. Butler, J. H. Gong, L. Bendall, C. Power, I. Clark-Lewis, C. M. Overall. 2001. Matrix metalloproteinase activity inactivates the CXC chemokine stromal cell-derived factor-1. J. Biol. Chem. 276: 43503-43508.[Abstract/Free Full Text]
  29. Delgado, M. B., I. Clark-Lewis, P. Loetscher, H. Langen, M. Thelen, M. Baggiolini, M. Wolf. 2001. Rapid inactivation of stromal cell-derived factor-1 by cathepsin G associated with lymphocytes. Eur. J. Immunol. 31: 699-707.[Medline]
  30. Proost, P., E. Schutyser, P. Menten, S. Struyf, A. Wuyts, G. Opdenakker, M. Detheux, M. Parmentier, C. Durinx, A. M. Lambeir, et al 2001. Amino-terminal truncation of CXCR3 agonists impairs receptor signaling and lymphocyte chemotaxis, while preserving antiangiogenic properties. Blood 98: 3554-3561.[Abstract/Free Full Text]
  31. Ludwig, A., F. Schiemann, R. Mentlein, B. Lindner, E. Brandt. 2002. Dipeptidyl peptidase IV (CD26) on T cells cleaves the CXC chemokine CXCL11 (I-TAC) and abolishes the stimulating but not the desensitizing potential of the chemokine. J. Leukocyte Biol. 72: 183-191.[Abstract/Free Full Text]
  32. McQuibban, G. A., J. H. Gong, J. P. Wong, J. L. Wallace, I. Clark-Lewis, C. M. Overall. 2002. Matrix metalloproteinase processing of monocyte chemoattractant proteins generates CC chemokine receptor antagonists with anti-inflammatory properties in vivo. Blood 100: 1160-1167.[Abstract/Free Full Text]
  33. Christopherson, K. W., II, G. Hangoc, H. E. Broxmeyer. 2002. Cell surface peptidase CD26/dipeptidylpeptidase IV regulates CXCL12/stromal cell-derived factor-1{alpha}-mediated chemotaxis of human cord blood CD34+ progenitor cells. J. Immunol. 169: 7000-7008.[Abstract/Free Full Text]
  34. Crump, M. P., J. H. Gong, P. Loetscher, K. Rajarathnam, A. Amara, F. Arenzana-Seisdedos, J.-L. Virelizier, M. Baggiolini, B. D. Sykes, I. Clark-Lewis. 1997. Solution structure and basis for functional activity of stromal cell-derived factor-1; dissociation of CXCR4 activation from binding and inhibition of HIV-1. EMBO J. 16: 6996-7007.[Medline]
  35. Weber, M., M. Uguccioni, M. Baggiolini, I. Clark-Lewis, C. A. Dahinden. 1996. Deletion of the NH2-terminal residue converts monocyte chemotactic protein 1 from an activator of basophil mediator release to an eosinophil chemoattractant. J. Exp. Med. 183: 681-685.[Abstract/Free Full Text]
  36. Struyf, S., I. De Meester, S. Scharpe, J. P. Lenaerts, P. Menten, J. M. Wang, P. Proost, J. van Damme. 1998. Natural truncation of RANTES abolishes signaling through CC chemokine receptors CCR1 and CCR3, impairs its chemotactic potency and generates a CC chemokine inhibitor. Eur. J. Immunol. 28: 1262-1271.[Medline]
  37. Oravecz, T., M. Pall, G. Roderiquez, M. D. Gorrell, M. Ditto, N. Y. Nguyen, R. Boykins, E. Unsworth, M. A. Norcross. 1997. Regulation of the receptor specificity and function of the chemokine RANTES by dipeptidyl peptidase IV (CD26)-mediated cleavage. J. Exp. Med. 186: 1865-1872.[Abstract/Free Full Text]
  38. Struyf, S., P. Proost, D. Schols, E. De Clercq, G. Opdenakker, J. P. Lenaerts, M. Detheux, M. Parmentier, I. De Meester, S. Scharpe, et al 1999. CD26/dipeptidyl peptidase IV down-regulates the eosinophil chemotactic potency, but not the anti-HIV activity of human eotaxin by affecting its interaction with CC chemokine receptor 3. J. Immunol. 162: 4903-4909.[Abstract/Free Full Text]
  39. He, S., Q. Peng, A. F. Walls. 1997. Potent induction of a neutrophil and eosinophil-rich infiltrate in vivo by human mast cell tryptase: selective enhancement of eosinophil recruitment by histamine. J. Immunol. 159: 6216-6225.[Abstract]
  40. He, S., A. F. Walls. 1998. Human mast cell chymase induces the accumulation of neutrophils, eosinophils and other inflammatory cells in vivo. Br. J. Pharmacol. 125: 1491-1500.[Medline]
  41. Tomimori, Y., T. Muto, H. Fukami, K. Saito, C. Horikawa, N. Tsuruoka, M. Saito, N. Sugiura, K. Yamashiro, M. Sumida, et al 2002. Chymase participates in chronic dermatitis by inducing eosinophil infiltration. Lab. Invest. 82: 789-794.[Medline]
  42. Tomimori, Y., N. Tsuruoka, H. Fukami, K. Saito, C. Horikawa, M. Saito, T. Muto, N. Sugiura, K. Yamashiro, M. Sumida, et al 2002. Role of mast cell chymase in allergen-induced biphasic skin reaction. Biochem. Pharmacol. 64: 1187.[Medline]
  43. Watanabe, N., K. Miura, Y. Fukuda. 2002. Chymase inhibitor ameliorates eosinophilia in mice infected with Nippostrongylus brasiliensis. Int. Arch. Allergy Immunol. 128: 235-239.[Medline]
  44. Watanabe, N., Y. Tomimori, K. Saito, K. Miura, A. Wada, M. Tsudzuki, Y. Fukuda. 2002. Chymase inhibitor improves dermatitis in NC/Nga mice. Int. Arch. Allergy Immunol. 128: 229-234.[Medline]
  45. Tani, K., F. Ogushi, H. Kido, T. Kawano, Y. Kunori, T. Kamimura, P. Cui, S. Sone. 2000. Chymase is a potent chemoattractant for human monocytes and neutrophils. J. Leukocyte Biol. 67: 585-589.[Abstract]
  46. Cui, P., K. Tani, H. Kitamura, Y. Okumura, M. Yano, D. Inui, T. Tamaki, S. Sone, H. Kido. 2001. A novel bioactive 31-amino acid endothelin-1 is a potent chemotactic peptide for human neutrophils and monocytes. J. Leukocyte Biol. 70: 306-312.[Abstract/Free Full Text]
  47. Grimshaw, M. J., J. L. Wilson, F. R. Balkwill. 2002. Endothelin-2 is a macrophage chemoattractant: implications for macrophage distribution in tumors. Eur. J. Immunol. 32: 2393-2400.[Medline]
  48. Chertov, O., H. Ueda, L. L. Xu, K. Tani, W. J. Murphy, J. M. Wang, O. M. Howard, T. J. Sayers, J. J. Oppenheim. 1997. Identification of human neutrophil-derived cathepsin G and azurocidin/CAP37 as chemoattractants for mononuclear cells and neutrophils. J. Exp. Med. 186: 739-747.[Abstract/Free Full Text]
  49. Moriuchi, H., M. Moriuchi, A. S. Fauci. 2000. Cathepsin G, a neutrophil-derived serine protease, increases susceptibility of macrophages to acute human immunodeficiency virus type 1 infection. J. Virol. 74: 6849-6855.[Abstract/Free Full Text]
  50. Tani, K., F. Ogushi, L. Huang, T. Kawano, H. Tada, N. Hariguchi, S. Sone. 2000. CD13/aminopeptidase N, a novel chemoattractant for T lymphocytes in pulmonary sarcoidosis. Am. J. Respir. Crit. Care Med. 161: 1636-1642.[Abstract/Free Full Text]
  51. Huang, L., K. Tani, F. Ogushi, H. Ogawa, T. Shimizu, Y. Motoki, H. Moriguchi, S. Sone. 2002. Role of CD13/aminopeptidase N in rat lymphocytic alveolitis caused by thoracic irradiation. Radiat. Res. 157: 191-198.[Medline]
  52. Shimizu, T., K. Tani, K. Hase, H. Ogawa, L. Huang, F. Shinomiya, S. Sone. 2002. CD13/aminopeptidase N-induced lymphocyte involvement in inflamed joints of patients with rheumatoid arthritis. Arthritis Rheum. 46: 2330-2338.[Medline]
  53. Poltorak, A. N., F. Bazzoni, I. I. Smirnova, E. Alejos, P. Thompson, G. Luheshi, N. Rothwell, B. Beutler. 1995. MIP-1{gamma}: molecular cloning, expression, and biological activities of a novel CC chemokine that is constitutively secreted in vivo. J. Inflamm. 45: 207-219.[Medline]
  54. Youn, B. S., I. K. Jang, H. E. Broxmeyer, S. Cooper, N. A. Jenkins, D. J. Gilbert, N. G. Copeland, T. A. Elick, M. J. Fraser, Jr, B. S. Kwon. 1995. A novel chemokine, macrophage inflammatory protein-related protein-2, inhibits colony formation of bone marrow myeloid progenitors. J. Immunol. 155: 2661-2667.[Abstract]
  55. Hara, T., K. B. Bacon, L. C. Cho, A. Yoshimura, Y. Morikawa, N. G. Copeland, D. J. Gilbert, N. A. Jenkins, T. J. Schall, A. Miyajima. 1995. Molecular cloning and functional characterization of a novel member of the C-C chemokine family. J. Immunol. 155: 5352-5358.[Abstract]
  56. Wu, Y., M. B. Prystowsky, A. Orlofsky. 1999. Sustained high-level production of murine chemokine C10 during chronic inflammation. Cytokine 11: 523-530.[Medline]
  57. Hogaboam, C. M., C. S. Gallinat, D. D. Taub, R. M. Strieter, S. L. Kunkel, N. W. Lukacs. 1999. Immunomodulatory role of C10 chemokine in a murine model of allergic bronchopulmonary aspergillosis. J. Immunol. 162: 6071-6079.[Abstract/Free Full Text]
  58. Zhao, X., A. Sato, C. S. De La Cruz, M. Linehan, A. Luegering, T. Kucharzik, A.-K. Shirakawa, G. Marquez, J. M. Farber, I. Williams, et al 2003. CCL9 is secreted by the follicle-associated epithelium and recruits dome regi